New NLRP3 Inhibitor BGE-102 Slashes Inflammation Markers by 85% in Phase 1 Trial
BioAge Labs has reported promising Phase 1 results for BGE-102, an oral pill that blocks the NLRP3 inflammasome — a key driver of chronic inflammation linked to heart disease, metabolic disorders, and aging. In participants with obesity and elevated inflammation, a 60mg daily dose reduced high-sensitivity C-reactive protein (hsCRP) by up to 86% over 21 days, with 87% of treated participants reaching healthy hsCRP levels below 2 mg/L. The drug was well-tolerated and showed effects comparable to a higher 120mg dose. BioAge plans to launch a Phase 2 cardiovascular trial in early 2026, with results expected later that year. If the drug continues to perform, it could become a significant tool for reducing cardiovascular and age-related inflammatory disease.